TERT and glioblastoma: Similarly, Zheng et al. demonstrated that integrating immunogenomic profiles with classical molecular determinants (e.g., EGFR amplification, PTEN loss, TERT mutations) enables the identification of clinically meaningful GBM clusters that differ in tumor microenvironment composition, immune evasion pathways, and predicted response to immunotherapy [53].